Home Featured Page 223

Featured

Latest

Oregon Psilocybin Services Tracker: Q1 2025

Reconstructing Meaning: Chris Timmermann on the Neurophenomenology of Psychedelics

Mattha Busby: Power, Pleasure, and the Psychedelic Movement’s Reckoning

Dylan Beynon – Mindbloom – At Home Ketamine

Beckley’s 5-MeO-DMT Shows Rapid, Durable Antidepressant Effects in Phase 2b Study

Psychedelics, Religion, and the DEA’s Quest for Soul

PT255 – Jasmine Virdi – Conservation, Covid, and Neurodivergence

Psychedelic Medicine Virtual Symposium – 8/28, 9/11, 9/25

PTSF72 – Breaking Down SB-519, with MAPS’ Ismail L. Ali

Optimi Health Joins First Psychedelic Exchange Traded Fund

Ian Burnstein Joins Wesana Health Advisory Board

Silo Wellness Announces Approval for Trading on the OTCQB Under Symbol...

Active vs. Passive Coping Distinguishes Antidepressants and Psychedelics

Psychedelic Research Bulletin: June 2021

PsyBio Therapeutics Augments Intellectual Property Portfolio with Filing of Next Novel...

1...222223224...292 Page 223 of 292

EDITOR PICKS

Oregon Psilocybin Services Tracker: Q1 2025

Reconstructing Meaning: Chris Timmermann on the Neurophenomenology of Psychedelics

Mattha Busby: Power, Pleasure, and the Psychedelic Movement’s Reckoning

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Oregon Psilocybin Services Tracker: Q1 2025

Reconstructing Meaning: Chris Timmermann on the Neurophenomenology of Psychedelics

Mattha Busby: Power, Pleasure, and the Psychedelic Movement’s Reckoning

Dylan Beynon – Mindbloom – At Home Ketamine

Beckley’s 5-MeO-DMT Shows Rapid, Durable Antidepressant Effects in Phase 2b Study

Psychedelics, Religion, and the DEA’s Quest for Soul

PT255 – Jasmine Virdi – Conservation, Covid, and Neurodivergence

Psychedelic Medicine Virtual Symposium – 8/28, 9/11, 9/25

PTSF72 – Breaking Down SB-519, with MAPS’ Ismail L. Ali

Optimi Health Joins First Psychedelic Exchange Traded Fund

Ian Burnstein Joins Wesana Health Advisory Board

Silo Wellness Announces Approval for Trading on the OTCQB Under Symbol...

Active vs. Passive Coping Distinguishes Antidepressants and Psychedelics

Psychedelic Research Bulletin: June 2021

PsyBio Therapeutics Augments Intellectual Property Portfolio with Filing of Next Novel...

EDITOR PICKS

Oregon Psilocybin Services Tracker: Q1 2025

Reconstructing Meaning: Chris Timmermann on the Neurophenomenology of Psychedelics

Mattha Busby: Power, Pleasure, and the Psychedelic Movement’s Reckoning

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY